Related Experiment Video
Updated: Jul 20, 2026

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Consumption of dietary supplements containing Citrus aurantium (bitter orange)--2004 California Behavioral Risk
Karl C Klontz1, Babgaleh B Timbo, Debra Street
1Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, MD 20740-3835, USA. karl.klontz@cfsan.fda.gov
Background:
Following the marketing ban of ephedra-containing supplements in April 2004, many manufacturers substituted the herb Citrus aurantium for ephedra and marketed the products as "ephedra-free" supplements. Extracts of C. aurantium contain synephrine, a sympathomimetic alkaloid.
Objective:
To determine the prevalence of consumption of dietary supplements containing C. aurantium in California during 2004.
Methods:
We used the 2004 California Behavioral Risk Factor Surveillance Survey to determine the prevalence of consumption of dietary supplements containing C. aurantium in California during 2004.
Results:
Two percent (n = 70) of the 4140 survey respondents reported taking a dietary supplement containing C. aurantium in the previous year. Reasons stated included energy enhancement, weight loss, and appetite suppression. Compared with nonusers, users were more likely to report being single, aged 18-34 years, and Hispanic; consuming 3 or more alcoholic drinks on days that they imbibed; and having a heavier body mass index. Among the 5 users who reported experiencing an adverse event that they attributed to the supplement, 3 indicated that the severity was mild.
Conclusions:
Given that supplements containing ephedra were banned in April 2004, the results from this study may serve as a baseline estimate against which future studies of the use of C. aurantium products may be compared.
Related Concept Videos
Cancer Prevention
Some...
Lifestyle Factors and Health
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...